Found 336 articles for: "eczema"
Supplement Individual Article: NECOM Skincare Algorithm for Patients With Cancer and Survivors
January 2023 | Volume 22 | Issue 1 | Supplement Individual Articles | 3595573 | Copyright © January 2023
Background: Cancer treatment-related cutaneous adverse events (cAEs) frequently occur, which can interfere with anticancer treatment outcomes and can severely impact quality of life f...
Read MoreA Review of the Challenges and Nuances in Treating Rosacea in Asian Skin Types Using Cleansers and Moisturizers as Adjuncts
January 2023 | Volume 22 | Issue 1 | Original Article | 45 | Copyright © January 2023
Background: Rosacea is primarily an inflammatory disease of facial skin associated with impaired skin barrier function. While it is commonly thought of as a Caucasian person's disease...
Read MoreTretinoin Review With Newer Formulations: Providing Effective and Tolerable Solutions in Clinical Practice
January 2023 | Volume 22 | Issue 1 | Original Article | 35 | Copyright © January 2023
Topical tretinoin has historically been limited by poor tolerability and molecular instability. Research advances have enhanced its efficacy and tolerability, along with reducing oxidation and photode...
Read MoreEffects of a Topical Growth Factor Regimen Following Pre-elected Cosmetic Facial Injection Procedures
January 2023 | Volume 22 | Issue 1 | Original Article | 9 | Copyright © January 2023
Background: There are limited studies evaluating topical cosmetic skincare products following cosmetic facial injections.
Objective: An open-label study assesse...
Read MoreNon-adherence to Labeling Standards Can Misrepresent Safety of Ingredients in Cosmetic Cleansers
January 2023 | Volume 22 | Issue 1 | Features | 98 | Copyright © January 2023
US Labeling requirements for cosmetic products are established by the US Food and Drug Administration (USFDA) and detailed in the Code of Federal Regulations (21 CFR 701.3).1 Over 16,000 co...
Read MoreJAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies
December 2022 | Volume 21 | Issue 12 | Original Article | 1298 | Copyright © December 2022
Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read MoreBacteriophages: An Alternative to Combat Antibiotic Resistance?
December 2022 | Volume 21 | Issue 12 | Original Article | 1311 | Copyright © December 2022
Background: Antibiotic resistance has become one of the largest pitfalls of modern medicine, and this has fueled the search for a safe and effective alternative. Of these alternatives...
Read MoreThe "Flolan Rash": An Impressively Asymptomatic and Non-Inflammatory Eruption Following Long-Term Epoprostenol Therapy
November 2022 | Volume 21 | Issue 11 | Case Reports | 1249 | Copyright © November 2022
Epoprostenol (Flolan) is a last-resort intravenous medication for the treatment of severe pulmonary arterial hypertension (PAH). Cutaneous adverse events of Flolan are well-known by pulmonologists, th...
Read MoreMeasuring and Improving Adherence to Crisaborole 2% Ointment in Patients With Atopic Dermatitis
October 2022 | Volume 21 | Issue 10 | Original Article | 1043 | Copyright © October 2022
Background: Atopic dermatitis (AD) is an inflammatory skin condition with dry, scaly, and intensely itchy skin. Treatment failure is the result of poor adherence.
Object...
Read MoreTreatment and Maintenance of Cutaneous Rosacea in Latino Skin Types With Prescription Medications and Non-Prescription Cleansers and Moisturizers as Adjuncts: A Review
October 2022 | Volume 21 | Issue 10 | Original Article | 1111 | Copyright © October 2022
Background: Rosacea is an inflammatory dermatosis with at least a ten percent prevalence reported among white adults. Rosacea occurs in nonwhite populations, but prevalence data is li...
Read MoreThe Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review
October 2022 | Volume 21 | Issue 10 | Original Article | 1070 | Copyright © October 2022
Background: Approximately 30% to 40% of alopecia areata (AA) patients have atopic dermatitis. Studies suggest that antihistamines and dupilumab may be effective treatments; however, t...
Read MorePhase 2 Trial of Topical Thykamine in Adults With Mild to Moderate Atopic Dermatitis
October 2022 | Volume 21 | Issue 10 | Original Article | 1091 | Copyright © October 2022
Background: Atopic dermatitis is a common skin disorder for which there remains an unmet need for topical pharmacotherapies that are safe and effective. This phase 2 study assessed th...
Read MorePharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum
October 2022 | Volume 21 | Issue 10 | Original Article | 1104 | Copyright © October 2022
Background: Berdazimer (SB206), gel 10.3% is a novel, topical, nitric oxide–releasing agent intended for molluscum contagiosum (MC) treatment.
Methods: A ...
Read MoreWhy Does Facial Eczema Differ From Body Eczema?
October 2022 | Volume 21 | Issue 10 | Case Reports | 1119 | Copyright © October 2022
Background: The pathophysiology of atopic dermatitis (AD) is multifactorial, influenced by genetics, skin barrier dysfunction, and environmental stressors. There is a lack of research...
Read MoreDermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials
October 2022 | Volume 21 | Issue 10 | Original Article | 1084 | Copyright © October 2022
Background: Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for psoriasis treatment and...
Read MoreSupplement Article: The Role of Epidermal Barrier Dysfunction and Cutaneous Microbiome Dysbiosis in the Pathogenesis and Management of Acne Vulgaris and Rosacea
September 2022 | Volume 21 | Issue 9 | Supplement Individual Articles | SF3502915 | Copyright © September 2022
Background: Dysregulation of either the cutaneous microbiome (CM) or epidermal barrier function (EBF) is thought to play an increasingly important role in acne vulgaris (AV) and rosac...
Read MoreEfficacy, Safety, and Applications of Skin Protectants
September 2022 | Volume 21 | Issue 9 | Original Article | 977 | Copyright © September 2022
The skin barrier is essential for protection against allergens, irritants, and pathogens and is intimately involved in a variety of inflammatory conditions. As such, approaches to treating these infla...
Read MoreSevere Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
August 2022 | Volume 21 | Issue 8 | Case Reports | 897 | Copyright © August 2022
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of ...
Read MoreInternational Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting
August 2022 | Volume 21 | Issue 8 | Original Article | 867 | Copyright © August 2022
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. It is composed of researchers and stakeholders who work to develop evidenc...
Read MoreUsage of Topical Calcineurin Inhibitors in the Medicare Population from 2013 to 2018
August 2022 | Volume 21 | Issue 8 | Editorials | 912 | Copyright © August 2022
Topical calcineurin inhibitors are a family of drugs that have been touted for having high efficacy without the risks of cutaneous atrophy and systemic absorption seen with topical corticosteroids. Th...
Read More